SCUBE2

Summary

SCUBE2 (signal peptide, CUB domain and EGF like domain containing 2, HGNC:30425) is a protein-coding gene on chromosome 11p15.4, encoding Signal peptide, CUB and EGF-like domain-containing protein 2 (Q9NQ36). Lipid-binding protein required for SHH long-range signaling by binding to the dually lipid-modified SHH (ShhNp) and by promoting ShhNp mobilization, solubilization and release from the cell membrane.

Predicted to enable calcium ion binding activity; hedgehog family protein binding activity; and lipid binding activity. Predicted to be involved in signal transduction. Predicted to act upstream of or within several processes, including chondrocyte differentiation involved in endochondral bone morphogenesis; positive regulation of chondrocyte proliferation; and positive regulation of osteoblast differentiation. Predicted to be located in extracellular region. Predicted to be active in cell surface and extracellular space.

Source: NCBI Gene 57758 — RefSeq curated summary.

At a glance

• GWAS associations: 4
• Clinical variants (ClinVar): 50 total
• MANE Select transcript: NM_001367977

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:30425
Approved symbol	SCUBE2
Name	signal peptide, CUB domain and EGF like domain containing 2
Location	11p15.4
Locus type	gene with protein product
Status	Approved
Aliases	Cegf1, Cegb1, FLJ16792
Ensembl gene	ENSG00000175356
Ensembl biotype	protein_coding
OMIM	611747
Entrez	57758

Gene structure

Transcript identifiers

Ensembl transcripts: 31 — 25 protein_coding, 3 retained_intron, 3 protein_coding_CDS_not_defined

ENST00000309263, ENST00000450649, ENST00000518447, ENST00000519202, ENST00000519535, ENST00000519788, ENST00000520467, ENST00000524317, ENST00000528651, ENST00000530265, ENST00000531429, ENST00000532532, ENST00000534295, ENST00000649792, ENST00000899093, ENST00000899094, ENST00000899095, ENST00000899096, ENST00000899097, ENST00000899098, ENST00000936074, ENST00000936075, ENST00000950241, ENST00000950242, ENST00000950243, ENST00000950244, ENST00000950245, ENST00000950246, ENST00000950247, ENST00000950248, ENST00000950249

RefSeq mRNA: 4 — MANE Select: NM_001367977 NM_001170690, NM_001330199, NM_001367977, NM_020974

CCDS: CCDS53599, CCDS7797, CCDS81553, CCDS91436

Canonical transcript exons

ENST00000649792 — 23 exons

Exon	Start	End
ENSE00001187336	9025702	9025854
ENSE00001187338	9027364	9027561
ENSE00001187350	9033626	9033796
ENSE00001187354	9047356	9047562
ENSE00001187358	9047943	9048098
ENSE00001187363	9050606	9050710
ENSE00001187366	9053099	9053215
ENSE00001187368	9053637	9053759
ENSE00001187371	9055793	9055909
ENSE00001187373	9059303	9059425
ENSE00001187376	9060408	9060524
ENSE00001187379	9065891	9065980
ENSE00001187382	9066697	9066813
ENSE00001187388	9069370	9069495
ENSE00001187392	9074481	9074615
ENSE00001187394	9079384	9079509
ENSE00001309105	9030758	9030925
ENSE00001728446	9052746	9052832
ENSE00002120071	9091396	9091599
ENSE00003516780	9029884	9030045
ENSE00003670189	9021876	9021955
ENSE00003670491	9089707	9089829
ENSE00003833113	9019476	9021197

Expression profiles

Bgee: expression breadth ubiquitous, 211 present calls, max score 93.75.

FANTOM5 (CAGE): breadth broad, TPM avg 3.5374 / max 81.5763, expressed in 322 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
118539	1.9051	207
118538	0.9638	143
118541	0.3033	170
118540	0.2694	97
118537	0.0736	31
118542	0.0221	8

Top tissues by expression

275 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
corpus epididymis	UBERON:0004359	93.75	gold quality
mammary duct	UBERON:0001765	92.86	gold quality
epithelium of mammary gland	UBERON:0003244	92.12	gold quality
right uterine tube	UBERON:0001302	92.02	gold quality
prostate gland	UBERON:0002367	91.21	gold quality
mucosa of urinary bladder	UBERON:0001259	91.08	gold quality
urinary bladder	UBERON:0001255	90.68	gold quality
thoracic mammary gland	UBERON:0005200	90.45	gold quality
mammary gland	UBERON:0001911	90.36	gold quality
adenohypophysis	UBERON:0002196	89.86	gold quality
body of stomach	UBERON:0001161	89.79	gold quality
pituitary gland	UBERON:0000007	89.64	gold quality
ectocervix	UBERON:0012249	89.14	gold quality
endocervix	UBERON:0000458	89.12	gold quality
lower esophagus mucosa	UBERON:0035834	88.13	gold quality
cartilage tissue	UBERON:0002418	87.66	gold quality
body of pancreas	UBERON:0001150	87.60	gold quality
stomach	UBERON:0000945	87.08	gold quality
omental fat pad	UBERON:0010414	86.88	gold quality
peritoneum	UBERON:0002358	86.84	gold quality
adipose tissue of abdominal region	UBERON:0007808	86.70	gold quality
subcutaneous adipose tissue	UBERON:0002190	86.48	gold quality
decidua	UBERON:0002450	85.90	gold quality
adipose tissue	UBERON:0001013	85.83	gold quality
fundus of stomach	UBERON:0001160	85.53	gold quality
muscle layer of sigmoid colon	UBERON:0035805	85.32	gold quality
connective tissue	UBERON:0002384	84.84	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	84.44	gold quality
colonic epithelium	UBERON:0000397	84.35	gold quality
mucosa of transverse colon	UBERON:0004991	84.28	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	6.70

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

40 targeting SCUBE2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-141-3P	99.94	72.79	2421
HSA-MIR-200A-3P	99.94	72.68	2420
HSA-MIR-4753-3P	99.90	71.03	3786
HSA-MIR-548E-5P	99.89	72.73	4486
HSA-MIR-6857-5P	99.87	65.32	985
HSA-MIR-548AC	99.84	70.77	4351
HSA-MIR-548H-3P	99.84	70.80	4349
HSA-MIR-548Z	99.84	70.80	4349
HSA-MIR-520F-3P	99.82	71.32	1216
HSA-MIR-6739-5P	99.80	67.87	2806
HSA-MIR-4766-5P	99.75	69.23	2662
HSA-MIR-6733-5P	99.74	67.94	2759
HSA-MIR-33A-3P	99.70	70.27	3362
HSA-MIR-298	99.63	67.56	1916
HSA-MIR-4516	99.61	67.78	3390
HSA-MIR-3153	99.55	67.59	2337
HSA-MIR-143-3P	99.49	69.05	1457
HSA-MIR-4770	99.49	69.09	1451
HSA-MIR-155-5P	99.35	70.16	1509
HSA-MIR-6088	99.29	68.45	1284
HSA-MIR-7974	99.24	65.48	1137
HSA-MIR-6780B-3P	99.13	67.18	622
HSA-MIR-4434	99.10	67.01	1984
HSA-MIR-5703	99.10	67.09	2053
HSA-MIR-4709-3P	98.88	68.04	1594
HSA-MIR-4742-3P	98.73	69.82	1803
HSA-MIR-12125	98.59	67.54	1044

Literature-anchored findings (GeneRIF, showing 22)

• identification as secreted protein that is expressed in vascular endothelium and may play important roles in development, inflammation, and thrombosis (PMID:12270931)
• Altered SCUBE2 expression is important in breast cancer progression and SCUBE2 may serve as a useful prognostic marker. (PMID:19369267)
• The full-length cDNA of human SCUBE2 was isolated and the role in the hedgehog signalling cascade, was studied. (PMID:19480626)
• Domain and functional analysis of a novel breast tumor suppressor protein, SCUBE2. (PMID:21652720)
• data suggest that signal peptide CUB domain (SCUBE2), like in breast cancer, associates with estrogen receptor alpha and might have a potential as prognostic or predictive marker in endometrial cancer (PMID:24053619)
• Via obligate assistance of Scube1 and 3, Scube2 plays a center role to recruit dually lipid-modified Hedgehog transferred from Dispatched A (DispA), increasing Hh secretion by promoting its solubility. (PMID:24084593)
• Tumor suppressor SCUBE2 inhibits breast-cancer cell migration and invasion through the reversal of epithelial-mesenchymal transition. (PMID:24213532)
• Sheddases and Scube2 act cooperatively to increase the pool of soluble bioactive Shh. (PMID:24522195)
• SCUBE2 expression was decreased at the transcriptional and translational levels in colorectal cancer tissues and significantly associated with clinical stage, the depth of tumor invasion, lymphnode metastasis, distant metastasis and histological grade. (PMID:25672935)
• Overexpression of SCUBE2 is associated with Breast Cancer Recurrence. (PMID:27165221)
• Results confirm that heparan sulfate (HS) proteoglycans enrich Scube2 at the surface of Shh-producing cells and that Scube2-regulated proteolytic Shh processing and release depends on specific HS. (PMID:27199253)
• The Sonic hedgehog (Shh) signaling pathway was involved in the inhibitory effect of SCUBE2 overexpression on glioma cells. (PMID:27697090)
• Endothelial SCUBE2 may be a novel coreceptor for VEGFR2 and potentiate VEGF-induced signaling in adult angiogenesis. (PMID:27834687)
• Overexpression of SCUBE2 inhibits non-small cell lung cancer cell proliferation and invasion through suppressing the Sonic hedgehog signaling pathway. (PMID:29883759)
• that SCUBE2 expression is upregulated in breast cancer stem cells, promote EMT and enhance TNBC metastasis by activating Notch signaling (PMID:29981340)
• this study reported for the first time that SCUBE2 methylation can be reversed by (-)-epigallocatechin-3-gallate treatment, finally resulting in the inhibition of breast cancer progression. (PMID:31404982)
• High SCUBE2 expression is associated with dyslipidemic type 2 diabetes mellitus. (PMID:31425950)
• The relationship of serum SCUBE-1, -2 and -3 levels with clinical findings and ultrasonographic skin thickness in systemic sclerosis patients. (PMID:31991528)
• Knockdown of long non-coding RNA PVT1 induces apoptosis of fibroblast-like synoviocytes through modulating miR-543-dependent SCUBE2 in rheumatoid arthritis. (PMID:32293498)
• Expression of SCUBE2 and BCL2 Predicts Favorable Response in ERalpha Positive Breast Cancer. (PMID:33878879)
• Knockdown of circ_0025908 inhibits proliferation, migration, invasion, and inflammation while stimulates apoptosis in fibroblast-like synoviocytes by regulating miR-650-dependent SCUBE2. (PMID:35904110)
• SCUBE2 mediates bone metastasis of luminal breast cancer by modulating immune-suppressive osteoblastic niches. (PMID:37142671)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	scube2	ENSDARG00000037362
mus_musculus	Scube2	ENSMUSG00000007279
rattus_norvegicus	Scube2	ENSRNOG00000013123

Paralogs (2): SCUBE3 (ENSG00000146197), SCUBE1 (ENSG00000159307)

Protein

Protein identifiers

Signal peptide, CUB and EGF-like domain-containing protein 2 — Q9NQ36 (reviewed: Q9NQ36)

Alternative names: Protein CEGP1, Scube/You

All UniProt accessions (6): A0A3B3ISZ7, Q9NQ36, H0YD28, H0YDN3, H0YEB3, H0YEI5

UniProt curated annotations — full annotation on UniProt →

Function. Lipid-binding protein required for SHH long-range signaling by binding to the dually lipid-modified SHH (ShhNp) and by promoting ShhNp mobilization, solubilization and release from the cell membrane. Acts by enhancing the proteolytic processing (shedding) of the lipid-modified N- and C- terminal of ShhNp at the cell surface. Synergizes with DISP1 to increase SHH secretion. Probable cell surface coreceptor for VEGFR2 involved in VEGFR2-mediated angiogenesis.

Subunit / interactions. Forms homooligomers. Forms heterooligomers with SCUBE1. Forms heterooligomers with SCUBE3. Interacts with SHH via the cholesterol anchor of the dually lipid-modified SHH (ShhNp). Interacts with PTCH1. Interacts with VEGFR2.

Subcellular location. Secreted. Cell surface.

Tissue specificity. Expressed in a broad spectrum of adult tissues.

Post-translational modifications. N-glycosylated.

Domain organisation. The CUB domain is important for the interaction with the cholesterol-anchor of SHH. The CUB domain regulates protease recruitment and activation during SHH shedding.

Isoforms (3)

UniProt ID	Names	Canonical?
Q9NQ36-1	1	yes
Q9NQ36-2	2
Q9NQ36-3	3

RefSeq proteins (4): NP_001164161, NP_001317128, NP_001354906, NP_066025 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000152	EGF-type_Asp/Asn_hydroxyl_site	PTM
IPR000742	EGF	Domain
IPR000859	CUB_dom	Domain
IPR001881	EGF-like_Ca-bd_dom	Domain
IPR009030	Growth_fac_rcpt_cys_sf	Homologous_superfamily
IPR011641	Tyr-kin_ephrin_A/B_rcpt-like	Domain
IPR018097	EGF_Ca-bd_CS	Conserved_site
IPR024731	NELL2-like_EGF	Domain
IPR026823	cEGF	Domain
IPR035914	Sperma_CUB_dom_sf	Homologous_superfamily
IPR049883	NOTCH1_EGF-like	Domain
IPR052071	SCUB_EGF-like_domain	Family

Pfam: PF00431, PF07645, PF07699, PF12662, PF12947, PF14670

UniProt features (38 total): disulfide bond 14, domain 10, sequence variant 5, splice variant 4, signal peptide 1, chain 1, region of interest 1, glycosylation site 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9NQ36-F1	72.78	0.07

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (14): 49–62, 56–71, 73–84, 90–102, 98–111, 113–126, 368–378, 374–387, 389–401, 407–418, 414–427, 429–442, 809–835, 862–883

Glycosylation sites (1): 659

Function

Pathways and Gene Ontology

Reactome pathways

4 pathways

ID	Pathway
R-HSA-5362798	Release of Hh-Np from the secreting cell
R-HSA-162582	Signal Transduction
R-HSA-5358346	Hedgehog ligand biogenesis
R-HSA-5358351	Signaling by Hedgehog

MSigDB gene sets: 109 (showing top): WANG_CLIM2_TARGETS_UP, JAEGER_METASTASIS_DN, BHATI_G2M_ARREST_BY_2METHOXYESTRADIOL_DN, AREB6_03, GOZGIT_ESR1_TARGETS_DN, MAZ_Q6, GOCC_CELL_SURFACE, SMID_BREAST_CANCER_RELAPSE_IN_LUNG_DN, CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_1, SMID_BREAST_CANCER_LUMINAL_B_UP, NF1_Q6_01, WTGAAAT_UNKNOWN, AACTTT_UNKNOWN, VANTVEER_BREAST_CANCER_POOR_PROGNOSIS, VECCHI_GASTRIC_CANCER_EARLY_DN

GO Biological Process (1): signal transduction (GO:0007165)

GO Molecular Function (3): calcium ion binding (GO:0005509), lipid binding (GO:0008289), protein binding (GO:0005515)

GO Cellular Component (3): extracellular region (GO:0005576), obsolete extracellular space (GO:0005615), cell surface (GO:0009986)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Hedgehog ligand biogenesis	1
Signaling by Hedgehog	1
Signal Transduction	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
binding	2
cellular anatomical structure	2
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
metal ion binding	1

Protein interactions and networks

STRING

1207 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SCUBE2	DENND2B	P78523	839
SCUBE2	CTSV	O60911	697
SCUBE2	LMO1	P25800	678
SCUBE2	GRB7	Q14451	664
SCUBE2	CDON	Q4KMG0	629
SCUBE2	DISP1	Q96F81	619
SCUBE2	MYBL2	P10244	585
SCUBE2	MMP11	P24347	578
SCUBE2	BAG1	Q99933	574
SCUBE2	GATA3	P23771	559
SCUBE2	HHAT	Q5VTY9	557
SCUBE2	AURKA	O14965	520
SCUBE2	SHH	Q15465	510
SCUBE2	GSTM1	P09488	505
SCUBE2	CDH1	P12830	480

IntAct

2 interactions, top by confidence:

A	B	Type	Score
SYNPO	SCUBE2	psi-mi:“MI:0915”(physical association)	0.400

BioGRID (3): KDR (Affinity Capture-Western), SCUBE2 (Affinity Capture-Western), SYNPO (Affinity Capture-MS)

ESM2 similar proteins: A0A096LNW5, B8JI71, D3ZHH1, G3I6Z6, O00548, O35516, O57409, P0DPK3, P0DPK4, P35442, P46531, P78504, P97677, Q01705, Q04721, Q05793, Q07008, Q08E66, Q2QI47, Q5G872, Q5ZQU0, Q61483, Q63722, Q66PY1, Q6DI48, Q6NZL8, Q70E20, Q7TQN3, Q7Z3S9, Q8IWY4, Q8IX30, Q8JZM4, Q8K3K1, Q8NFT8, Q8TER0, Q8TEU8, Q8UWJ4, Q8VHS2, Q90Y54, Q90Y57

Diamond homologs: A0A6I8RMG7, A2AJ76, B3EWY9, B5DFC9, O35568, O77469, O88322, P10493, P14543, P41413, P48960, P98095, Q04592, Q09165, Q14112, Q19267, Q2KIT5, Q2Q421, Q2Q426, Q4G063, Q4V7F2, Q4V7M2, Q5EA46, Q5RBP1, Q5XH36, Q60438, Q6UXH1, Q6UXI9, Q7SXF6, Q7ZXL5, Q86XX4, Q8BPB5, Q8K4G1, Q8R4U0, Q8R4Y4, Q91XD7, Q96HD1, Q96RW7, Q9CYA0, Q9JJS0

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

50 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	45
Likely benign	2
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

4386 predictions. Top by Δscore:

Variant	Effect	Δscore
11:9021871:CTCA:C	donor_loss	1.0000
11:9021872:TCA:T	donor_loss	1.0000
11:9021873:CA:C	donor_loss	1.0000
11:9021874:A:AT	donor_loss	1.0000
11:9021875:C:CT	donor_loss	1.0000
11:9021951:GTCCT:G	acceptor_gain	1.0000
11:9021952:TCCT:T	acceptor_gain	1.0000
11:9021953:CCTC:C	acceptor_gain	1.0000
11:9021954:CT:C	acceptor_gain	1.0000
11:9021954:CTCTG:C	acceptor_loss	1.0000
11:9021955:TCTGT:T	acceptor_loss	1.0000
11:9021956:C:CC	acceptor_gain	1.0000
11:9021956:C:CG	acceptor_loss	1.0000
11:9021957:T:A	acceptor_loss	1.0000
11:9021959:T:C	acceptor_gain	1.0000
11:9021959:T:TC	acceptor_gain	1.0000
11:9024257:T:TA	donor_gain	1.0000
11:9027362:A:AC	donor_gain	1.0000
11:9027363:C:CC	donor_gain	1.0000
11:9027399:T:TA	donor_gain	1.0000
11:9029882:A:AC	donor_gain	1.0000
11:9029883:C:CC	donor_gain	1.0000
11:9029885:TTTAC:T	donor_gain	1.0000
11:9029889:CA:C	donor_gain	1.0000
11:9030042:TGAA:T	acceptor_gain	1.0000
11:9030046:C:CC	acceptor_gain	1.0000
11:9030063:G:C	acceptor_gain	1.0000
11:9030063:G:GC	acceptor_gain	1.0000
11:9030754:TCAC:T	donor_loss	1.0000
11:9030755:CACC:C	donor_loss	1.0000

AlphaMissense

6781 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
11:9021085:A:G	L987P	1.000
11:9021163:A:G	L961P	1.000
11:9021163:A:T	L961Q	1.000
11:9021175:A:G	L957P	1.000
11:9021880:A:G	L948P	1.000
11:9021922:C:G	R934P	1.000
11:9021925:A:T	V933D	1.000
11:9021928:A:T	I932K	1.000
11:9021940:A:G	L928P	1.000
11:9025708:A:C	Y921D	1.000
11:9025717:A:C	Y918D	1.000
11:9025793:G:C	F892L	1.000
11:9025793:G:T	F892L	1.000
11:9025794:A:C	F892C	1.000
11:9025794:A:G	F892S	1.000
11:9025795:A:G	F892L	1.000
11:9025797:G:T	A891D	1.000
11:9027381:A:G	L866P	1.000
11:9027435:A:G	L848P	1.000
11:9027444:C:G	R845P	1.000
11:9027469:A:G	W837R	1.000
11:9027469:A:T	W837R	1.000
11:9027475:A:G	C835R	1.000
11:9021063:A:C	F994L	0.999
11:9021063:A:T	F994L	0.999
11:9021065:A:G	F994L	0.999
11:9021096:G:C	F983L	0.999
11:9021096:G:T	F983L	0.999
11:9021097:A:C	F983C	0.999
11:9021097:A:G	F983S	0.999

dbSNP variants (sampled 300 via entrez): RS1000002302 (11:9071110 C>T), RS1000005310 (11:9059210 C>A,G), RS1000084338 (11:9059641 C>A,T), RS1000142630 (11:9019795 T>G), RS1000161568 (11:9054906 G>C), RS1000175494 (11:9020095 C>G,T), RS1000181222 (11:9068559 T>C), RS1000225911 (11:9021497 G>A), RS1000267209 (11:9058868 G>T), RS1000281364 (11:9065194 C>A,T), RS1000358642 (11:9059051 T>G), RS1000399756 (11:9071158 C>T), RS1000406572 (11:9027773 G>A), RS1000420617 (11:9092986 C>T), RS1000430695 (11:9071564 G>T)

Disease associations

OMIM: gene MIM:611747 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST001800_2	β2-Glycoprotein I (β2-GPI) plasma levels	1.000000e-07
GCST001800_3	β2-Glycoprotein I (β2-GPI) plasma levels	3.000000e-07
GCST010278_7	Hand grip strength (Mahalanobis distance)	7.000000e-06
GCST010703_171	Brain morphology (MOSTest)	5.000000e-09

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0004555	glycoprotein measurement
EFO:0006941	grip strength measurement
EFO:0004346	neuroimaging measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

35 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression, affects expression	7
trichostatin A	affects cotreatment, decreases expression	3
bisphenol A	increases expression	2
mercuric bromide	decreases expression, affects cotreatment	2
entinostat	affects cotreatment, decreases expression	2
Panobinostat	affects cotreatment, decreases expression	2
Benzo(a)pyrene	increases expression, increases methylation	2
Nickel	decreases expression	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
p-Chloromercuribenzoic Acid	decreases expression, affects cotreatment	2
aristolochic acid I	increases expression	1
methylmercuric chloride	decreases expression	1
tetrachlorodian	decreases expression	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
bisphenol S	affects cotreatment, decreases expression	1
Arsenic Trioxide	decreases expression	1
Arsenic	affects methylation	1
Calcitriol	increases expression, affects cotreatment	1
Carbamazepine	affects expression	1
Cyclophosphamide	affects cotreatment, affects response to substance	1
Dexamethasone	affects cotreatment, decreases expression	1
Doxorubicin	affects cotreatment, affects response to substance	1
Estradiol	decreases expression	1
Ethinyl Estradiol	decreases expression	1
Fluorouracil	affects cotreatment, affects response to substance	1
Indomethacin	affects cotreatment, decreases expression	1
Silicon Dioxide	decreases expression	1
Testosterone	affects cotreatment, increases expression, decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.